Page last updated: 2024-11-08

vernodalin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vernodalin: RN given for (3aR-(3aalpha,4alpha,5aalpha,9aalpha,9bbeta))-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID179375
CHEMBL ID251225
CHEBI ID9959
SCHEMBL ID23589779
MeSH IDM0438757

Synonyms (14)

Synonym
C09576 ,
21871-10-3
vernodalin
CHEMBL251225 ,
chebi:9959 ,
[(3ar,4s,5ar,9ar,9br)-5a-ethenyl-3,9-dimethylidene-2,8-dioxo-3a,4,5,6,9a,9b-hexahydrofuro[2,3-f]isochromen-4-yl] 2-(hydroxymethyl)prop-2-enoate
2-propenoic acid, 2-(hydroxymethyl)-, 5a-ethenyldecahydro-3,9-bis(methylene)-2,8-dioxo-2h-furo(2,3-f)(2)benzopyran-4-yl ester, (3ar-(3aalpha,4alpha,5aalpha,9aalpha,9bbeta))-
2h-furo(2,3-f)(2)benzopyran-2,8(3h)-dione, 3abeta,4,5,5a,6,9,9abeta,9balpha-octahydro-4beta-hydroxy-3,9-dimethylene-5abeta-vinyl-, 2-methylenehydracrylate, (+)-
hydracrylic acid, 2-methylene-, ester with 3abeta,4,5,5a,6,9,9abeta,9balpha-octahydro-4beta-hydroxy-3,9-dimethylene-5abeta-vinyl-2h-furo(2,3-f)(2)benzopyran-2,8(3h)-dione, (+)-
2-propenoic acid, 2-(hydroxymethyl)-, (3ar,4s,5ar,9ar,9br)-5a-ethenyldecahydro-3,9-bis(methylene)-2,8-dioxo-2h-furo(2,3-f)(2)benzopyran-4-yl ester
5a-ethenyl-3,9-dimethylidene-2,8-dioxodecahydro-2h-furo[2,3-f][2]benzopyran-4-yl 2-(hydroxymethyl)prop-2-enoate
DTXSID20944472
Q27108533
SCHEMBL23589779

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
carbonyl compoundAny compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1311309Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by WST-8 assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
New sesquiterpene lactones, vernonilides A and B, from the seeds of Vernonia anthelmintica in Uyghur and their antiproliferative activities.
AID1311311Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by WST-8 assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
New sesquiterpene lactones, vernonilides A and B, from the seeds of Vernonia anthelmintica in Uyghur and their antiproliferative activities.
AID310936Cytotoxicity against human KB cells2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Quantitative structure-activity relationship of sesquiterpene lactones with cytotoxic activity.
AID1311310Antiproliferation activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by WST-8 assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
New sesquiterpene lactones, vernonilides A and B, from the seeds of Vernonia anthelmintica in Uyghur and their antiproliferative activities.
AID387024Cytotoxicity against human KB cells2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Use of self-organizing maps and molecular descriptors to predict the cytotoxic activity of sesquiterpene lactones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (30.00)29.6817
2010's5 (50.00)24.3611
2020's2 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.97 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]